<DOC>
	<DOC>NCT02114931</DOC>
	<brief_summary>The purpose of this open-label study is to evaluate the long-term safety and efficacy of ABP 501.</brief_summary>
	<brief_title>Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Subject was randomized into protocol 20120262 and has completed the week 26 visit Subject experienced a serious adverse event (SAE) or an adverse event (AE) in the 20120262 study that could cause extension treatment to be detrimental Subject has completed study 20120262 but cannot be dosed within 4 weeks of the week 26 visit of study 20120262 Current infection requiring the use of oral or intravenous antibiotics Other Inclusion/Exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>81 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>arthritis</keyword>
	<keyword>rheumatoid</keyword>
</DOC>